

FORMATO EUROPEO PER IL CURRICULUM VITAE



INFORMAZIONI PERSONALI

Nome	Giuseppe Danilo Norata
Indirizzo	Via Meda 26 – 20900 Monza, MB (Italia)
Telefono	02 50318313-293
Fax	02 50318386
E-mail	Danilo.Norata@unimi.it
Nazionalità	Italiana
Data e luogo di nascita	Monza, 02 Gennaio 1973
Codice fiscale	NRTGPP73A02F704C

CV BREVE

Il Dr. Norata si è laureato nel 1996 in Farmacia presso l'Università degli Studi di Milano, ha poi conseguito il Dottorato di Ricerca in Medicina Sperimentale, presso l'Università degli Studi di Siena e la Specializzazione in Farmacologia. Nel 2003 consegue la seconda laurea in Biotecnologie Farmaceutiche presso l'Università degli Studi di Milano. Dal 2002 al 2004 trascorre diversi periodi come ricercatore ospite presso il Karolinska Institute, Stoccolma, Svezia, sempre in questo periodo fino al 2005 è assegnista di ricerca presso il Dipartimento di Scienze Farmacologiche, Università degli Studi di Milano. Dal 2005 a tutt'oggi è responsabile del Laboratorio di Genetica Molecolare e Genomica Cardiovascolare presso il Centro SISA per lo Studio dell'Aterosclerosi Ospedale Bassini. Dal 2008 al 2014 il Dr. Norata è stato ricercatore universitario settore BIO14, Farmacologia, presso il Dipartimento di Scienze Farmacologiche, Università degli Studi di Milano. Da Gennaio 2015 il Dr. Norata è Professore Associato di Farmacologia, presso il Dipartimento di Scienze Farmacologiche, Università degli Studi di Milano dove insegna discipline attinenti alla Farmacologia. Il Dr. Norata è autore di oltre 120 pubblicazioni su riviste peer-reviewed con un impact factor totale di 620 e medio di 6.1; è revisore di più di 50 riviste internazionali nel campo cardiometabolico e farmacologico ed è membro di numerose società scientifiche; ha partecipato inoltre in qualità di relatore o moderatore a diversi meeting nazionali ed internazionali.

E' stato insignito di numerosi premi nazionali per la ricerca oltre al prestigioso riconoscimento per giovani ricercatori del European Lipoprotein Club nel 2005 e della European Atherosclerosis Society nel 2010.

Il Dr. Norata ha una vasta esperienza nello studio dei meccanismi molecolari coinvolti nelle malattie vascolari e cardiometaboliche mediante studi in vitro ed in vivo. Il laboratorio del Dr. Norata è equipaggiato per studi di genomica funzionale e genetica molecolare con utilizzo della piattaforma cDNA microarray e di real time PCR quantitativa, per studi con colture cellulari e di biologia molecolare oltre a numerosi modelli murini transgenici di disfunzione endoteliale, aterosclerosi e malattie cardiovascolari. Attraverso la collaborazione con il Centro per lo Studio dell'Aterosclerosi dell'Ospedale Bassini, il Dr. Norata ha accesso ai campioni biologici e il DNA di studi osservazionali nella popolazione generale come lo studio PLIC.

IMPIEGO ATTUALE

• Date (da – a)	2015 -oggi
• Nome e indirizzo del datore di lavoro	Dipartimento di Scienze Farmacologiche, Facoltà di Farmacia, via Balzaretti 9 - Milano

- Tipo di azienda o settore
 - Tipo di impiego
 - Principali mansioni e responsabilità
- **Date (da – a)**
- Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
 - Principali mansioni e responsabilità
- **Date (da – a)**
- Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
 - Principali mansioni e responsabilità

Università degli Studi di Milano

Professore Associato settore disciplinare 05/G1 Farmacologia BIO-14.

- Insegnamento di discipline correlate alla Farmacologia agli studenti dei Corsi di Laurea della Facoltà di Farmacia e di Scienze del Farmaco.

2008 -2014

Dipartimento di Scienze Farmacologiche, Facoltà di Farmacia, via Balzaretti 9 - Milano

Università degli Studi di Milano

Ricercatore Universitario settore disciplinare 05/G1 Farmacologia BIO-14.

- Insegnamento di discipline correlate alla Farmacologia agli studenti dei Corsi di Laurea della Facoltà di Farmacia e di Scienze del Farmaco.

2005 ad oggi

Società Italiana Studio Aterosclerosi, Sez Lombardia, via Balzaretti 7 Milano

Centro per lo Studio dell'Aterosclerosi, Ospedale Bassini, Cinisello Balsamo, Milano.

Responsabile del Laboratorio di Genetica Molecolare e Genomica Cardiovascolare.

-Organizzazione e pianificazione della ricerca in ambito cardiovascolare.

CURRICULUM SCIENTIFICO

- **Date (da – a)**
 - Nome e tipo di istituto di istruzione o formazione
 - Principali materie / abilità professionali oggetto dello studio
- **Date (da – a)**
- Nome e tipo di istituto di istruzione o formazione
 - Principali materie / abilità professionali oggetto dello studio
- **Date (da – a)**
- Nome e tipo di istituto di istruzione o formazione
 - Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita
 - Livello nella classificazione nazionale (se pertinente)
- **Data**
- Nome e tipo di istituto di istruzione o formazione
 - Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita
 - Livello nella classificazione nazionale (se pertinente)
- **Data**
- Nome e tipo di istituto di istruzione o formazione
 - Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita
 - Livello nella classificazione nazionale (se pertinente)
- **Date (da – a)**
- Nome e tipo di istituto di istruzione

2002-2005

Assegno di Ricerca, Dipartimento di Scienze Farmacologiche, Università degli Studi di Milano.

Ricerca di base ed applicata in campo cardiovascolare.

2002-2004

Visiting Scientist, Atherosclerosis Research Unit, Karolinska Hospital, Karolinska Institute, Stoccolma, Svezia.

Ricerca in campo genetico e di genomica cardiovascolare

2003

Seconda Laurea in Biotecnologie Farmaceutiche, Università degli Studi di Milano

Biotecnologie applicate alla ricerca biomedica

Laurea

110/110 e lode

2002

Scuola di Specialità in Farmacologia, Facoltà di Farmacia, Università degli Studi di Milano.

Farmacologia

Specializzazione in Farmacologia

70/70 e lode

1998-2001

Dottorato di Ricerca in Medicina Sperimentale, Università degli Studi di Siena

o formazione	
• Principali materie / abilità professionali oggetto dello studio	Medicina Sperimentale
• Qualifica conseguita	Dottore di Ricerca (PhD)
• Data	1996
• Nome e tipo di istituto di istruzione o formazione	Laurea in Farmacia, Università degli Studi di Milano
• Principali materie / abilità professionali oggetto dello studio	Discipline Farmaceutiche
• Qualifica conseguita	Laurea
• Livello nella classificazione nazionale (se pertinente)	110/110 e lode

PUBBLICAZIONI

Cluster-assembled zirconia substrates promote long term differentiation and functioning of human islets of Langerhans

Galli A, Maffioli E, Sogne E, Moretti S, di Cairano ES, Negri A, Nonnis S, Norata GD, Bonacina F, Borghi F, Podesta A, Bertuzzi F, Milani P, Lenardi C, Tedeschi G, Perego C
Scientific Reports, 2018; in press. **IF 4.122**

Biological consequences of dysfunctional HDL

Pirillo [A](#), [Catapano AL](#), [Norata GD](#)

Current Medicinal Chemistry, 2018; in press. **IF 3.469**

Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth

Pacella I, Procaccini C, Focaccetti C, Miacci S, Timperi E, Faicchia D, Severa M, Rizzo F, Coccia EM, Bonacina F, Mitro N, Norata GD, Rossetti G, Ranzani V, Pagani M, Giorda E, Wei Y, Matarese G, Barnaba V, Piconese S.

Proceedings of the National Academy of Sciences, 2018; in press. **IF 9.504**

Myeloid Apolipoprotein E controls Dendritic Cell antigen presentation function and adaptive immunity.

Bonacina F, Coe D, Wang G, Longhi MP, Baragetti A, Moregola A, Garlaschelli K, Uboldi P, Pellegatta F, Grigore L, Da Dalt L, Annoni A, Gregori S, Xiao Q, Caruso D, Mitro N, Catapano AL, Marelli-Berg FM, Norata GD.

Nature Communication, 2018; in press. **IF 12.353**

PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the LDL receptor.

Da Dalt L, Ruscica M, Bonacina F, Balzarotti G, Dhyani A, Di Cairano E, Baragetti A, Arnaboldi L, De Metrio S, Pellegatta F, Grigore L, Botta M, Macchi C, Uboldi P, Perego C, Catapano AL, Norata GD.

European Heart Journal, 2018; in press. **IF 23.425**

Trained immunity and cardiovascular disease: is it time for translation to humans?

Norata GD.

Cardiovascular Research, 2018;114:e41-e42. **IF 6.290**

Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps.

Baragetti A, Grejtakova D, Casula M, Olmastroni E, Jotti GS, **Norata GD**, Catapano AL, Bellosta S.

Pharmacological Research. 2018;130:1-11. **IF 4.897**

The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis.

Pirillo A, Bonacina F, **Norata GD**, Catapano AL.

Current Atherosclerosis Report. 2018;20:12. **IF 2.560**

Predictive value for cardiovascular events of common carotid intima media thickness and its rate

of change in individuals at high cardiovascular risk - Results from the PROG-IMT collaboration.
Lorenz MW, Gao L, Ziegelbauer K, **Norata GD**, Empana JP, Schmidtmann I, Lin HJ, McLachlan S, Bokemark L, Ronkainen K, Amato M, Schminke U, Srinivasan SR, Lind L, Okazaki S, Stehouwer CDA, Willeit P, Polak JF, Steinmetz H, Sander D, Poppert H, Desvarieux M, Ikram MA, Johnsen SH, Staub D, Sirtori CR, Iglseider B, Beloqui O, Engström G, Frier A, Rozza F, Xie W, Parraga G, Grigore L, Plichart M, Blankenberg S, Su TC, Schmidt C, Tuomainen TP, Veglia F, Völzke H, Nijpels G, Willeit J, Sacco RL, Franco OH, Uthoff H, Hedblad B, Suarez C, Izzo R, Zhao D, Wannarong T, Catapano A, Ducimetiere P, Espinola-Klein C, Chien KL, Price JF, Bergström G, Kauhanen J, Tremoli E, Dörr M, Berenson G, Kitagawa K, Dekker JM, Kiechl S, Sitzer M, Bickel H, Rundek T, Hofman A, Mathiesen EB, Castelnuevo S, Landecho MF, Rosvall M, Gabriel R, de Luca N, Liu J, Baldassarre D, Kavousi M, de Groot E, Bots ML, Yanez DN, Thompson SG; PROG-IMT study group.

PLOSone 2018;13:e0191172. **IF 2.766**

Zc3h10 is a novel mitochondrial regulator.

Audano M, Pedretti S, Cermenati G, Brioschi E, Diaferia G, Ghisletti S, Cuomo A, Bonaldi T, Salerno F, Mora M, Grigore L, Garlaschelli K, Baragetti A, Bonacina F, Catapano AL, **Norata GD**, Crestani M, Caruso D, Saez E, De Fabiani E, Mitro N.

Embo Reports 2018;9.pii: e45531. **IF 8.749**

Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis.

Kishore M, Cheung KCP, Fu H, Bonacina F, Wang G, Coe D, Ward EJ, Colamatteo A, Jangani M, Baragetti A, Matarese G, Smith DM, Haas R, Mauro C, Wraith DC, Okkenhaug K, Catapano AL, De Rosa V, **Norata GD**, Marelli-Berg FM.

Immunity. 2017;47:875-889. **IF 19.734**

Disease trends over time and CD4+CCR5+ T-cells expansion predict carotid atherosclerosis development in patients with systemic lupus erythematosus.

Baragetti A, Ramirez GA, Magnoni M, Garlaschelli K, Grigore L, Berteotti M, Scotti I, Bozzolo E, Berti A, Camici PG, Catapano AL, Manfredi AA, Ammirati E, **Norata GD**.

Nutr Metab Cardiovasc Dis. 2018;28(1):53-63. **IF 3.318**

Targeting cholesterol in non-ischemic heart failure: a role for LDLR gene therapy?

Catapano AL, Pirillo A, **Norata GD**.

Molecular Therapy. 2017;25:2435-2437. **IF 7.008**

Strategies for the use of Non-Statin therapies

PirilloA, **Norata GD**, Catapano AL

Current Opinion Lipidology. 2017;28:458-464. **IF 3.853**

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives.

Catapano AL, Pirillo A, **Norata GD**

Vascular Health Risk Management. 2017;13:343-51

PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans.

Baragetti A, Balzarotti G, Grigore L, Pellegatta F, Guerrini U, Pisano G, Fracanzani AL, Fargion S, **Norata GD**, Catapano AL.

European Journal of Preventive Cardiology. 2017;24:1870-1877. **IF 4.542**

Advances in Hypercholesterolemia.

Pirillo A, **Norata GD**, Catapano AL

Medicinal Chemistry III vol. 7, pp. 663–93. Oxford: Elsevier

PCSK9 inhibition in statin-intolerant HeFH patients: What's new?

Casula M, Pirillo A, **Norata GD**, Catapano AL.

European Journal of Preventive Cardiology. 2017;24:1525-7 **IF 4.542**

Arctigenin improves vascular tone and decreases inflammation in human saphenous vein.

Daci A, Neziri B, Krasniqi S, Cavolli R, Alaj R, **Norata GD**, Beretta G.

Eur J Pharmacol. 2017;810:51-6. **IF 3.040**

PROG-IMT study group. Automatic identification of variables in epidemiological datasets using

logic regression.

Lorenz MW, Abdi NA, Scheckenbach F, Pflug A, Bülbül A, Catapano AL, Agewall S, Ezhov M, Bots ML, Kiechl S, Orth A for PROGIMT study.
BMC Med Inform Decis Mak. 2017;17:40

Long pentraxin PTX3 as a prognostic marker of cardiovascular mortality in patients with chronic kidney disease.

Baragetti A, **Norata GD**.
Pol Arch Intern Med. 2017;127:152-153.

A past and present overview of macrophage metabolism and functional outcomes.

Curi R, de Siqueira Mendes R, de Campos Crispin LA, **Norata GD**, Sampaio SC, Newsholme P.
Clinical Science. 2017;131:1329-1342. **IF 5.220**

mTORC1 activity repression by late endosomal phosphatidylinositol 3,4-bisphosphate

Marat AL, Wallroth A, Lo WT, Müller R, **Norata GD**, Falasca M, Schultz C, Haucke V.
Science 2017;356:968-972. **IF 41.058**

Vascular inflammation and low density lipoproteins: is cholesterol the link? A lesson from the clinical trials.

Catapano AL, Pirillo A, **Norata GD**.
British Journal of Pharmacology 2017; 174:3973-3985. **IF 6.810**

Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease.

De Gonzalo-Calvo D, Cenarro A, Garlaschelli K, Pellegatta F, Vilades D, Nasarre L, Camino-Lopez S, Crespo J, Carreras F, Leta R, Catapano AL, **Norata GD**, Civeira F, Llorente-Cortes V.
Journal of Molecular and Cellular Cardiology 2017;106:55-67. **IF 5.296**

T follicular helper cells promote a beneficial gut ecosystem for host metabolic homeostasis by sensing microbiota derived extracellular ATP.

Perruzza L, Gargari G, Proietti M, Fosso B, D'Erchia AM, Faliti CE, Rezzonico-Jost T, Scribano D, Mauri L, Colombo D, Pellegrini G, Moregola A, Mooser C, Pesole G, Nicoletti M, **Norata GD**, Geuking MB, McCoy KD, Guglielmetti S, Grassi F.
Cell Reports 2017;18:2566-2575. **IF 8.032**

Obesity-induced metabolic stress leads to biased effector memory CD4+T cell differentiation via PI3K p110d/Akt-mediated signals.

Mauro C, Smith J, Cucchi D, Coe D, Fu H, Bonacina F, Baragetti A, Cermenati G, Caruso D, Mitro N, Catapano AL, Ammirati E, Longhi MP, Okkenhaug K, **Norata GD**, Marelli-Berg FM.
Cell Metabolism 2017;25:593-609. **IF 20.565**

Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: gaps and open questions.

Ruscica M, Baragetti A, Catapano AL, **Norata GD**.
Nutrition Metabolism and Cardiovascular Disease 2017;27:379-395. **IF 3.318**

Circulating CD14+ and CD14highCD16- classical monocytes are reduced in patients with signs of plaque neovascularization in the carotid artery.

Ammirati E, Moroni F, Magnoni M, Di Terlizzi S, Villa C, Sizzano F, Palini A, Garlaschelli K, Tripiciano F, Scotti I, Catapano AL, Manfredi AA, **Norata GD**, Camici PG.
Atherosclerosis 2016; 255:171-178. **IF 4.239**

Biology of PCSK9: beyond LDL cholesterol lowering.

Norata GD, Tavori H, Pirillo A, Fazio S, Catapano AL.
Cardiovascular Research 2016;112:429-42. **IF 5.878**

Genetically determined telomeres shortening is associated with carotid atherosclerosis progression and increased incidence of cardiovascular events.

Baragetti A, Palmen J, Garlaschelli K, Grigore L, Humphries S, Talmud PJ, Catapano AL, **Norata GD**.
International Journal of Cardiology 2016;223:43-45. **IF 6.189**

Epicardial adipose tissue (EAT) thickness is associated with cardiovascular and liver damage in

nonalcoholic fatty liver disease.

Fracanzani AL, Pisano G, Baragetti A, Consonni D, Tiraboschi S, Bertelli C, **Norata GD**, Dongiovanni P, Valenti L, Grigore L, Tonella T, Catapano AL, Fargion S. PLoSone 2016;11(9):e0162473. **IF 2.806**

Vascular pentraxin 3 controls arterial thrombosis by targeting collagen and fibrinogen induced platelets aggregation.

Bonacina F, Barbieri SS, Cutuli L, Amadio P, Doni A, Sironi M, Tartari S, Mantovani A, Bottazzi B, Garlanda C, Tremoli E, Catapano AL, **Norata GD**. Biochimica Biophysica Acta 2016;1862:1182-90. **IF 5.476**

Applicability of the 2013 ACC/AHA Risk Assessment and Cholesterol Treatment Guidelines in the Real World: Results from a Multiethnic Case-Control Study.

Magnoni M, Berteotti M, **Norata GD**, Limite LR, Peretto G, Cristell N, Maseri A, Cianflone D. Annals of Medicine 2016;48(4):282-92. **IF 3.715**

Niemann-Pick C1-Like 1 (NPC1L1) inhibition and cardiovascular diseases.

Pirillo A, Catapano AL, **Norata GD**. Current Medicinal Chemistry 2016;23:983-99. **IF 3.455**

Progression of carotid vascular damage and cardiovascular events in non alcoholic fatty liver disease patients compared to the general population during 10 Years of follow-up.

Fracanzani AL, Tiraboschi S, Pisano G, Consonni D, Baragetti A, Bertelli C, **Norata GD**, Valenti L, Grigore L, Porzio M, Catapano AL, Fargion S. Atherosclerosis 2016;246:208-13. **IF 4.239**

Normative values for carotid intima media thickness and its progression: Are they transferrable outside of their cohort of origin?

Liao X, **Norata GD**, Polak JF, Stehouwer CD, Catapano A, Rundek T, Ezhov M, Sander D, Thompson SG, Lorenz MW; PROG-IMT study group. Eur J Prev Cardiol. 2016;23:1165-73. **IF 3.606**

Subclinical atherosclerosis is associated with Epicardial Fat Thickness and hepatic steatosis in the general population.

Baragetti A, Pisano G, Bertelli C, Garlaschelli K, Grigore L, Fracanzani AL, Fargion S, **Norata GD**, Catapano AL. Nutrition Metabolism and Cardiovascular Disease 2016; 26(2):141-53. **IF 3.679**

Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, metabolism and pharmacoresistance in a population of kosovar albanian epileptic patients.

Daci A, Beretta G, Villasaliu D, Shala A, Govori V, **Norata GD**, Krasniqi S. PLoS One. 2015 Nov 10;10(11):e0142408. **IF 3.057**

The cellular and molecular basis of translational immunometabolism.

Norata GD, Caligiuri G, Chavakis T, Matarese G, Netea MG, Nicoletti A, O'Neill LAJ, Marelli-Berg FM. Immunity 2015;43:421-34. **IF 24.082**

Functional Analysis of a Carotid Intima-Media Thickness Locus Implicates BCAR1 and Suggests a Causal Variant.

Boardman-Pretty F, Smith AJ, Cooper J, Palmen J, Folkersen L, Hamsten A, Catapano AL, Melander O, Price JF, Kumari M, Deanfield JE, Kivimäki M, Gertow K, Baragetti A, **Norata GD**, Humphries SE. Circulation Cardiovascular Genetics 2015;8:696-706. **IF 3.719**

Apolipoprotein C-III: from pathophysiology to pharmacology.

Norata GD, Pirillo A, Tsimikas S, Catapano AL. Trends in Pharmacological Sciences 2015;36:675-687. **IF 11.840**

Carotid Intima Media Thickness progression and risk of vascular events in people with diabetes mellitus- results from the PROG-IMT collaboration.

PROG-IMT collaboration. Diabetes Care 2015;38:1921-9. **IF 8.934**

PI3K-C2 γ 3 is a Rab5 effector selectively controlling endosomal Akt2 activation downstream insulin signaling.

Braccini L, Ciraolo E, Campa CC, Perino A, Longo DL, Tibolla G, Pregnolato M, Cao Y, Tassone B, Damilano F, Laffargue M, Calautti E, Falasca M, **Norata GD**, Backer J, Hirsch E. Nature Communications 2015;6:7400 **IF 11.329**

Peak inflammation in atherosclerosis, primary biliary cirrhosis and autoimmune arthritis is counter-intuitively associated with regulatory T cell enrichment.

Garetto S, Trovato AE, Lleo A, Sala F, Martini E, Betz AG, **Norata GD**, Invernizzi P, Kallikourdis M. Immunobiology 2015;220(8):1025-9. **IF 2.871**

Markers of inflammation associated with plaque progression and instability in patients with carotid atherosclerotic.

Ammirati E, Moroni F, **Norata GD**, Magnoni M, Camici PG. Mediators of Inflammation 2015;718329. **IF 3.418**

An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode.

Doni A, Musso T, Morone D, Bastone A, Zambelli V, Sironi M, Castagnoli C, Cambieri I, Stravalaci M, Pasqualini F, Laface I, Valentino S, Tartari S, Ponzetta A, Maina V, Barbieri SS, Tremoli E, Catapano AL, **Norata GD**, Bottazzi B, Garlanda C, Mantovani A. Journal of Experimental Medicine 2015;212(6):905-25. **IF 11.240**

IDOL N342S Variant, atherosclerosis progression and cardiovascular Disorders in the Italian general population.

Dhyani A, Tibolla G, Baragetti A, Garlaschelli K, Pellegatta F, Grigore L, **Norata GD**, Catapano AL. PLoS One. 2015;10:e0122414. **IF 3.057**

Fibronectin extra domain A stabilizes atherosclerotic plaque phenotype in apolipoprotein E and in LDL-receptor-deficient mice.

Pulakazhi Venu VK, Uboldi P, Dhyani A, Patrini A, Baetta R, Nicola Ferri N, Corsini A, Andrés F. Muro F, Catapano AL, **Norata GD**. Thrombosis and Haemostasis 2015;114:186-97. **IF 5.255**

Homozygous familial hypobetalipoproteinemia: two novel mutations in the splicing sites of apolipoprotein B gene and review of the literature.

Cefalù AB, **Norata GD**, Ghiglionni DG, Noto D, Uboldi P, Garlaschelli K, Baragetti A, Spina R, Valenti V, Pederiva C, Riva E, Terracciano L, Zoja A, Grigore L, Averna MR, Catapano AL. Atherosclerosis 2015, 239(1):209-17. **IF 3.942**

HDL in Infectious Diseases and Sepsis.

Pirillo A, Catapano AL, **Norata GD**. Handb Exp Pharmacol. 2015;224:483-508.

Impact of systemic inflammation and autoimmune diseases on apoA-I and HDL plasma levels and functions.

Montecucco F, Favari E, **Norata GD**, Ronda N, Nofer J, Vuilleumier N. Handb Exp Pharmacol. 2015;224:455-482.

Inflammatory markers and extent and progression of early atherosclerosis: meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration.

Willeit P, Thompson SG, Agewall S, Bergström G, Bickel H, Catapano AL, Chien KL, de Groot E, Empena JP, Etgen T, Franco OH, Iglseder B, Johnsen SH, Kavousi M, Lind L, Liu J, Mathiesen EB, **Norata GD**, Olsen MH, Papagianni A, Poppert H, Price JF, Sacco RL, Yanez DN, Zhao D, Schminke U, Bülbül A, Polak JF, Sitzer M, Hofman A, Grigore L, Dörr M, Su TC, Ducimetière P, Xie W, Ronkainen K, Kiechl S, Rundek T, Robertson C, Fagerberg B, Bokemark L, Steinmetz H, Arfan Ikram M, Völzke H, Lin HJ, Plichart M, Tuomainen TP, Desvarieux M, McLachlan S, Schmidt C, Kauhanen J, Willeit J, Lorenz MW, Sander D; for the PROG-IMT study group. European Journal of Preventive Cardiology 2016; 23(2):194-205. **IF 3.361**

The arachidonic acid metabolome as conserved regulator of cholesterol metabolism.

Demetz E, Schroll A, Auer K, Heim C, Patsch JR, Eller P, Theurl M, Theurl I, Theurl M, Seifert M,

Lener D, Stanzl U, Haschka D, Asshoff M, Dichtl S, Nairz M, Huber E, Stadlinger M, Li X, Pallweber P, Scharnagl H, Stojakovic T, März W, Kleber ME, Garlaschelli K, Uboldi P, Catapano AL, Stellaard F, Rudling M, Kuba K, Imai Y, Arita M, Pramstaller PP, Tietge UJF, Trauner M, **Norata GD**, Claudel T, Hicks AA, Weiss G, Tancevski I.
Cell Metabolism 2014;20:787-798. **IF 17.565**

PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges.
Norata GD, Tibolla G, Catapano AL
Vascular Pharmacology 2014;62:103-111. **IF 3.635**

Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk.

Walsh KM, Codd V, Smirnov IV, Rice T, Decker PA, Hansen HM, Kollmeyer T, Kosel ML, Molinaro AM, McCoy LS, Bracci PM, Cabriga BS, Pekmezci M, Zheng S, Wiemels JL, Pico AR, Tihan T, Berger MS, Chang SM, Prados MD, Lachance DH, O'Neill BP, Sicotte H, Eckel Passow JE; ENGAGE Consortium Telomere Group, van der Harst P, Wiencke JK, Samani NJ, Jenkins RB, Wrensch MR. Collaborators: Codd V, Nelson CP, Albrecht E, Mangino M, Deelen J, Buxton JL, Hottenga JJ, Fischer K, Esko T, Surakka I, Broer L, Nyholt DR, Leach IM, Salo P, Hägg S, Matthews MK, Palmen J, **Norata GD**, O'Reilly PF, Saleheen D, Amin N, Balmforth AJ, Beekman M, de Boer RA, Böhringer S, Braund PS, Burton PR, de Craen AJ, Denniff M, Dong Y, Douroudis K, Dubinina E, Eriksson JG, Garlaschelli K, Guo D, Hartikainen AL, Henders AK, Houwing-Duistermaat JJ, Kananen L, Karssen LC, Kettunen J, Klopp N, Lagou V, van Leeuwen EM, Madden PA, Mägi R, Magnusson PK, Männistö S, McCarthy MI, Medland SE, Mihailov E, Montgomery GW, Oostra BA, Palotie A, Peters A, Pollard H, Pouta A, Prokopenko I, Ripatti S, Salomaa V, Suchiman H, Valdes AM, Verweij N, Viñuela A, Wang X, Wichmann HE, Widen E, Willemssen G, Wright MJ, Xia K, Xiao X, van Veldhuisen DJ, Catapano AL, Tobin MD, Hall AS, Blakemore AI, van Gilst WH, Zhu H, Erdmann J, Reilly MP, Kathiresan S, Schunkert H, Talmud PJ, Pedersen NL, Perola M, Ouwehand W, Kaprio J, Martin NG, van Duijn CM, Hovatta I, Gieger C, Metspalu A, Boomsma DI, Jarvelin MR, Slagboom P, Thompson JR, Spector TD, van der Harst P, Samani NJ.
Nature Genetics 2014; 46:731-5. **IF 29.352**

Inibitori di PCSK9 e dislipidemie: le evidenze cliniche.
Norata GD.
Giornale Italiano di Cardiologia 2014;15:301-305.

HDL in innate and adaptive immunity.
Catapano AL, Pirillo A, Bonacina F, **Norata GD**.
Cardiovascular Research 2014;103:372-383. **IF 5.940**

Telomere shortening over 6 years is associated with increased subclinical carotid vascular damage and worse cardiovascular prognosis in the general population: results from the PLIC study.

Baragetti A, Palmen J, Garlaschelli K, Grigore L, Pellegatta F, Tragni, E, Catapano AL, Humphries S, **Norata GD**, Talmud PJ.
Journal of Internal Medicine 2015;277:478-87. **IF 7.803**

Novel concepts in HDL pharmacology.
Remaley AT, **Norata GD**, Catapano AL.
Cardiovascular Research 2014 103:423-428. **IF 5.940**

New therapeutic principles for familial hypercholesterolemia.
Norata GD.
Clinical Biochemistry 2014;47:756. **IF 2.275**

MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr^{-/-} mice.
Sala F, Aranda JF, Rotllan N, Ramírez CM, Aryal B, Elia L, Condorelli G, Catapano AL, Fernández-Hernando C, **Norata GD**.
Thrombosis and Haemostasis 2014;112:796-802. **IF 4.984**

Statins and skeletal muscles toxicity: from clinical trials to everyday practice
Norata GD, Tibolla G, Catapano AL.
Pharmacological Research 2014;88:107-113. **IF 4.408**

HDL to treat or not to treat?

Pirillo A, **Norata GD**, Catapano AL.

Current Atherosclerosis Report 2014;16:429. **IF 3.417**

Statins and periodontal inflammation: a pleiotropic effect of statins or a pleiotropic effect of LDL-cholesterol lowering?

Norata GD, Catapano AL.

Atherosclerosis 2014;234:381-82. **IF 3.994**

Postprandial lipidemia as a cardiometabolic risk factor.

Pirillo A, **Norata GD**, Catapano AL.

Current Medical Research & Opinion 2014;30:1489-1503. **IF 2.653**

Cardiometabolic and immune factors associated with increased common carotid artery Intima Media Thickness and cardiovascular diseases in patients with systemic lupus erythematosus.

Ammirati E, Bozzolo EO, Contri R, Baragetti A, Palini AG, Cianflone D, Banfi M, Uboldi P, Scotti I, Pirillo A, Grigore L, Garlaschelli K, Monaco C, Catapano AL, Sabbadini MG, Manfredi AA, **Norata GD**.

Nutrition Metabolism and Cardiovascular Disease 2014;24:751-759. **IF 3.323**

The missing link between high-density lipoprotein cholesterol and inflammatory response in cardiovascular disease.

Ammirati E, Scotti I, **Norata GD**.

Journal of the American College of Cardiology 2014;63:2747-2748. **IF 16.503**

Pentraxin 3 (PTX3) plasma levels and carotid intima media thickness progression in the general population.

Baragetti A, Knoflach M, Cuccovillo I, Grigore L, Casula M, Garlaschelli K, Mantovani A, Wick G, Kiechl S, Willeit J, Bottazzi B, Catapano AL, **Norata GD**.

Nutrition Metabolism and Cardiovascular Disease 2014;24:518-23. **IF 3.323**

Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society.

Soreni M et al on behalf of the metabolic syndrome Study Group.

Acta Diabetologica. 2013;50:241-249. **IF 2.679**

The thyroid receptor modulator KB3495 reduces atherosclerosis independently of total cholesterol in the circulation in ApoE deficient mice.

Mork LM, Rehnmark S, Davoodpour P, **Norata GD**, Larsson L, Witt MR, Malm J, Parini P.

PLOS One. 2013; 8:e78534. **IF 3.534**

Targeting PCSK9 for hypercholesterolemia.

Norata GD, Tibolla G, Catapano AL.

Annual Review of Pharmacology and Toxicology 2014;54:273-93. **IF 18.365**

The long pentraxin PTX3: a biomarker spanning from cardiovascular to cancer.

Falasca M, Bonacina F, Catapano AL, **Norata GD**.

Journal of Molecular Biomarkers and Diagnosis 2013;4:2.

LOX-1, OxLDL and atherosclerosis

Pirillo A, **Norata GD**, Catapano AL.

Mediators of Inflammation 2013;2013:152786. **IF 2.417**

New targets and developments in lipoproteins control.

Norata GD.

Research Reports in Clinical Cardiology 2013;4:1-8.

Prevalence of classical CD14⁺⁺/CD16⁻ but not of intermediate CD14⁺⁺/CD16⁺ monocytes in hypoalphalipoproteinemia.

Sala F, Cutuli L, Grigore G, Pirillo A, Chiesa G, Catapano AL, **Norata GD**.

International Journal of Cardiology 2013;S0167-5273(13)00534-2. **IF 6.175**

The CD1d-Natural Killer T cell axis in atherosclerosis.

Bondarenko S, Catapano AL, **Norata GD**.

Journal of Innate Immunity 2013; 6:3-12.- IF 4.557

High density lipoproteins cholesterol levels are an independent predictor of the progression of chronic kidney disease.

Baragetti A, **Norata GD**, Sarcina C, Rastelli F, Grigore L, Garlaschelli K, Ubaldi P, Baragetti I, Pozzi C, Catapano AL.

Journal of Internal Medicine 2013;274:252-62. IF 5.785

Long pentraxin 3 (PTX3): experimental and clinical relevance in cardiovascular diseases.

Bonacina F, Baragetti A, Catapano AL, **Norata GD**.

Mediators of Inflammation 2013;2013:725102. IF 2.417

New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs.

Norata GD, Ballantyne CM, Catapano AL.

European Heart Journal 2013;34:1783-9. IF 14.723

-374 T/ARAGE polymorphism is associated with chronic kidney disease progression in subjects affected by a nephrocardiovascular disease.

Baragetti I, **Norata GD**, Sarcina C, Baragetti A, Rastelli F, Buzzi L, Grigore L, Garlaschelli K, Pozzi C, Catapano AL.

PLOS One. 2013; 8:e60089. IF 3.534.

Gene silencing approaches for the management of dyslipidemia.

Norata GD, Tibolla G, Catapano AL.

Trends in Pharmacological Sciences 2013;34:198-205. IF 9.988

LDL Lowering Drugs: Current Perspectives

Norata GD.

Cardiovascular Pharmacology 2012;1:2.

European Lipoprotein Club: Report of the 35th ELC Annual Conference

Costet P, Ehrenborg E, Fisher R, Fielding B, Groen A, Kardassis D, Malle E, Mulder M, Niemeier A, **Norata GD**, Hansen AT, Eckardstein Av.

Atherosclerosis. 2013;226:510-6. IF 3.971

HDL subfractions: what the clinicians need to know.

Pirillo A, **Norata GD**, Catapano AL.

Cardiology 2013;124:116-125. IF 2.044

Class II Phosphoinositide 3-kinases contribute to endothelial cells morphogenesis.

Tibolla G, Piñeiro R, Chiozzotto D, Mavrommati I, Wheeler AP, **Norata GD**, Catapano AL, Maffucci T, Falasca M.

PLOS One. 2013; 8:e53808. IF 3.534

MicroRNAs and lipoproteins: a connection beyond atherosclerosis?

Norata GD, Sala F, Catapano AL, Fernández-Hernando C.

Atherosclerosis 2013;227:209-15. IF 3.971

Identification of seven loci affecting mean telomere length and their association with disease.

Codd V, Nelson CP, Albrecht E, Mangino M, Deelen J, Buxton JL, Hottenga JJ, Fischer K, Esko T, Surakka I, Broer L, Nyholt DR, Leach IM, Salo P, Hägg S, Matthews MK, Palmen J, **Norata GD**, O'Reilly PF, Saleheen D, Amin N, Balmforth AJ, Beekman M, de Boer RA, Böhringer S, Braund PS, Burton PR, de Craen AJM, Denniff M, Dong Y, Douroudis K, Dubinina E, Eriksson JG, Garlaschelli K, Guo D, Hartikainen AL, Henders AK, Houwing-Duistermaat JJ, Kananen L, Karssen LC, Kettunen J, Klopp N, Lagou V, van Leeuwen EM, Madden P, Mägi R, Magnusson PKE, Männistö S, McCarthy MI, Medland SE, Mihailov E, Montgomery GW, Oostra BA, Palotie A, Peters A, Pollard H, Pouta A, Prokopenko I, Ripatti S, Salomaa V, Suchiman HED, Valdes AM, Verweij N, Vinuela A, Wang X, Wichmann HE, Widen E, Willemsen G, Wright MJ, Xia K, Xiao X, van Veldhuisen DJ, Catapano AL, Tobin MD, Hall AS, Blakemore AIF, van Gilst WH, Zhu H, CARDIoGRAM consortium, Erdmann J, Reilly MP, Kathiresan S, Schunkert H, Talmud PJ, Pedersen NL, Perola M, Ouwehand W, Kaprio J, Martin NG, van Duijn CM, Hovatta I, Gieger C, Metspalu A, Boomsma D, Jarvelin MR, Slagboom PE, Thompson JR, Spector TD, van der Harst P, Samani NJ.

Nature Genetics 2013;45(4):422-7. **IF 29.648**

Pharmacogenetics in cardiovascular disorders: an update on the principal drugs
Predazzi IM, Mango R, **Norata GD**, Di Daniele N, Sergi D, Romeo F, Novelli G.
American Journal of Cardiovascular Drugs 2013;13:79-85. **IF 2.203**

High Density Lipoproteins and atherosclerosis: emerging aspects.
Sala F, Catapano AL, **Norata GD**.
Journal of Geriatric Cardiology 2012;9:401-407.

LOX-1 inhibition in ApoE KO mice using a Schizophyllan-based antisense oligonucleotide therapy.
Amati F, Diano L, Vecchione L, **Norata GD**, Koyama Y, Cutuli L, Catapano AL, Romeo F, Ando H, Novelli G.
Molecular Therapy Nucleic Acids 2012;1:e58.

Treating high density lipoprotein cholesterol (HDL-C): quantity versus quality.
Pirillo A, **Norata GD**, Catapano AL.
Current Pharmaceutical Design 2013;19:3841-57. **IF 3.288**

Established and Emerging Approaches for The Management of Dyslipidaemia.
Norata GD.
Scientifica 2012; vol. 2012, Article ID 482423, 14 pages.

HDL and adaptive immunity: a tale of lipid rafts.
Norata GD, Catapano AL.
Atherosclerosis 2012;225:34-5. **IF 3.706**

Effects of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia.
Grigore G, Raselli S, Garlaschelli K, Redaelli L, **Norata GD**, Pirillo A, Catapano AL.
European Journal of Clinical Pharmacology 2013;69:341-6 **IF 2.741**

Antigen-dependent and antigen-independent pathways modulate CD4+CD28null T cells during atherosclerosis.
Ammirati E, Monaco C, **Norata GD**.
Circulation Research 2012;111 e48-e49. **IF 11.861**

Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data.
Lorenz MW et al, on behalf of the PROG-IMT Study Group.
Lancet 2012;379:2053-2062 **IF 39.060**

A CYP26B1 polymorphism enhances retinoic acid catabolism which may aggravate atherosclerosis.
Krivospitskaya O, Elmabsout AA, Sundman E, Söderström LA, Ovchinnikova O, Gidlöf AC, Scherbak N, **Norata GD**, Samnegård A, Törmä H, Abdel-Halim SM, Jansson JH, Eriksson P, Sirsjö A and Olofsson PS.
Molecular Medicine 2012;18:712-718. **IF 4.469**

Leonurine: a new comer in the natural compounds affecting atherosclerosis.
Norata GD, Catapano AL.
Atherosclerosis 2012;224:37-38. **IF 3.706**

MicroRNA 143-145 deficiency impairs vascular function.
Norata GD, Pinna C, Zappella F, Elia L, Sala A, Condorelli G, Catapano AL.
International Journal of Immunopathology and Pharmacology 2012;25:467-484. **IF 2.685**

Effect of Tie-2 conditional deletion of BDNF on atherosclerosis in the ApoE null mutant mouse.
Norata GD, Pulakazhi Venu VK, Callegari E, Paloschi V, Catapano AL.
Biochimica et Biophysica Acta - Molecular Basis of Disease 2012;1822:927-935. **IF 4.910**

Long Pentraxin 3/tumor necrosis factor-stimulated gene-6 interaction a biological rheostat for

fibroblast growth factor 2-mediated angiogenesis.

Leali D, Inforzato A, Ronca R, Belleri M, Coltrini D, Bianchi R, Di Salle E, Sironi M, **Norata GD**, Bottazzi B, Garlanda C, Day AJ, Presta M.
Arteriosclerosis Thrombosis Vascular Biology 2012;32:696-70. **IF 6.338**

Effector memory T cells are associated with atherosclerosis in humans and animal models.
Ammirati E, Cianflone D, Vecchio V, Banfi M, Vermi AC, De Metrio M, Grigore L, Pellegatta F, Pirillo A, Garlaschelli K, Manfredi AA, Catapano AL, Maseri A, Palini A, **Norata GD**.
Journal of the American Heart Association. 2012;1:27-41

Association between OLR1 K167N SNP and intima media thickness of the common carotid artery in the general population.

Predazzi IM, **Norata GD**, Vecchione L, Garlaschelli K, Amati F, Grigore G, Cutuli L, Pirillo A, Romeo F, Novelli G, Catapano AL.
PLOS One. 2012;7:e31086. **IF 3.730**

Association between the adherence to AHA Step 1 nutrition criteria and the cardiometabolic outcome in the general population a two year follow-up study

Redaelli L, Garlaschelli K, Grigore G, **Norata GD**, Catapano AL.
Food and Nutrition Sciences. 2012;3:274-280.

Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition

Tibolla G, **Norata GD**, Artali R, Meneghetti F, Catapano AL.
Nutrition Metabolism and Cardiovascular Disease 2011; 21:835-43. **IF 3.731**

High Density Lipoproteins, immunity and atherosclerosis

Norata GD, Pirillo A, Catapano AL.
Current Opinion in Lipidology 2011;22:410-6. **IF 6.086**

Emerging role of High Density Lipoproteins as a player in the immune system.

Norata GD, Pirillo A, Ammirati E, Catapano AL.
Atherosclerosis 2012;220:11-21 **IF 3.794**

Therapy and clinical trials: aggressive statin therapy vs combined and emerging approaches.

Catapano AL, **Norata GD**, Pirillo A.
Current Opinion in Lipidology 2011;22:324-25. **IF 6.086**

Immunità ed aterosclerosi: aspetti emergenti.

Norata GD, Ammirati E, Cutuli L, Catapano AL.
Il Giornale dell'Aterosclerosi. 2011;1:13-24.

Novel biotinylated bile acid amphiphiles: micellar aggregates formation and interaction with hepatocytes.

Rizzi L, Braschi M, Colombo M, Vaiana N, Tibolla G, **Norata GD**, Catapano AL, Romeo S, Propseri D.
Organic and Biomolecular Chemistry 2011;9(8):2899-905. **IF 3.696**

Circulating CD4+CD25hiCD127lo regulatory T-cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis.

Ammirati E, Cianflone D, Banfi M, Vecchio V, Palini A, De Metrio M, Marenzi G, Panciroli C, Tumminello G, Anzuini A, Palloschi A, Grigore L, Garlaschelli K, Tramontana S, Tavano D, Airolidi F, Manfredi AA, Catapano AL, **Norata GD**.
Arteriosclerosis Thrombosis Vascular Biology 2010; 30(9):1832-41. **IF 7.215**

The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits tumor necrosis factor alpha and lipopolysaccharide induced inflammatory response in human endothelial cells and in mice aorta.

Norata GD, Cattaneo P, Poletti A, Catapano AL.
Atherosclerosis 2010; 212:100-6. **IF 4.086**

The long pentraxin PTX3: a modulator of the immuno-inflammatory response in atherosclerosis and cardiovascular diseases.

Norata GD, Garlanda C, Catapano AL.

Trends in Cardiovascular Medicine 2010;20:35-40. **IF 3.250**

Individual progression of carotid intima media thickness as a surrogate for vascular risk (PROG-IMT) - rationale and design of a meta-analysis project.

Lorenz MW, Bickel H, Bots ML, Breteler MMB, Catapano AL, Desvarieux M, Hedblad B, Iglseder B, Johnsen SH, Juraska M, Kiech S, Mathiesen EB, **Norata GD**, Grigore L, Polak J, Poppert H, Rosvall M, Rundek T, Sacco RL, Sander D, Sitzler M, Steinmetz H, Stensland E, Willeit J, Witteman J, Yanez D, Thompson SG, Prof. The PROG-IMT Study Group.

American Heart Journal 2010; 159:730-736. **IF 5.052**

Lecithin: Cholesterol Acyltransferase and vascular disease.

Norata GD, Catapano AL.

Clinical Lipidology 2010;5:13-15.

Increased atherosclerosis and vascular inflammation in APP transgenic mice with Apolipoprotein E deficiency.

Tibolla G, **Norata GD**, Meda C, Arnaboldi L, Ubaldi P, Piazza F, Ferrarese C, Corsini A, Maggi A, Vegeto E, Catapano AL.

Atherosclerosis 2010; 210:78-87. **IF 4.086**

Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles.

Norata GD, Garlaschelli K, Grigore L, Raselli S, Tramontana S, Meneghetti F, Artali R, Noto D, Cefalù AD, Buccianti G, Aversa M, Catapano AL.

Atherosclerosis 2010; 208:177-82. **IF 4.086**

Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis.

Norata GD, Marchesi P, Pulakazhi Venu VK, Pasqualini F, Anselmo A, Moalli F, Pizzitola I, Garlanda C, Mantovani A, Catapano AL.

Circulation 2009; 120:699-708. **IF 14.816**

Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells.

Norata GD, Raselli S, Grigore L, Garlaschelli K, Vianello D, Bertocco S, Zambon A, Catapano AL.

Atherosclerosis 2009; 206:556-62. **IF 4.522**

Plasma adiponectin levels in chronic kidney disease patients: relation with molecular inflammatory profile and metabolic status.

Norata GD, Baragetti I, Raselli S, Stucchi A, Garlaschelli K, Vettoretti S, Piloni G, Buccianti G, Catapano AL.

Nutrition Metabolism and Cardiovascular Disease 2010;20:56-63. **IF 3.438**

La microalbuminuria è un marcatore indipendente di danno cardiovascolare subclinico in soggetti affetti da disfunzione renale cronica.

Baragetti I, Buzzi L, Stucchi A, Sarcina C, Buccianti G, Catapano AL, **Norata GD**.

Il Bassini; volume XXVIII Gennaio-Giugno 2008;26-31.

Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population.

Norata GD, Garlaschelli K, Grigore L, Tibolla G, Raselli S, Redaelli L, Buccianti G, Catapano AL.

Nutrition Metabolism and Cardiovascular Disease 2009;19:129-134. **IF 3.517**

Il tessuto adiposo come possibile bersaglio di danno cardiovascolare in corso di disfunzione renale.

Baragetti I, **Norata GD**, Raselli S, Stucchi A, Terranno V, Catapano AL, Buccianti G.

Il Bassini; volume XXVII Luglio-Dicembre 2007;9-13.

The long pentraxin 3, a key component of innate immunity, is modulated by high density lipoproteins in endothelial cells.

Norata GD, Marchesi P, Pirillo A, Ubaldi P, Chiesa G, Maina V, Garlanda C, Mantovani A, Catapano AL.

Arteriosclerosis Thrombosis Vascular Biology 2008;28:925-931. **IF 6.858**

The relationship between leptin: Adiponectin ratio and carotid intima-media thickness in asymptomatic females - Response to letter by Kotani et al.

Norata GD, Magni P, Catapano AL.

Stroke 2008;39:e34. **IF 6.499**

Combination therapy in cholesterol reduction: focus on ezetimibe and statins.

Grigore L, **Norata GD**, Catapano AL.

Vascular Health and Risk Management 2008; 4:1-12.

Citazioni: 22

Inhibition of synthesis and absorption of cholesterol: a new option in managing hypercholesterolemia.

Grigore L, **Norata GD**, Catapano AL.

International Congress Series 2007; 1303:121-128.

Leptin: adiponectin ratio is an independent predictor of intima-media thickness of the common carotid artery.

Norata GD, Raselli S, Grigore L, Garlaschelli K, Dozio E, Magni P, Catapano AL

Stroke 2007;38:2844-2846. **IF 6.296**

ApoE gene delivery inhibits severe hypercholesterolemia in newborn ApoE-KO mice.

Signori E, Rinaldi M, Fioretti D, Iurescia S, Seripa D, Perrone G, **Norata GD**, Catapano AL, Fazio VM.

Biochem Biophys Res Comm 2007;361:543-548. **IF 2.749**

Associazione tra polimorfismo -374T/A del RAGE e gravità della disfunzione renale in pazienti affetti da insufficienza renale cronica (IRC)

Stucchi A, Terranno V, Baragetti I, Tibolla G, Vettoretti S, Raselli S, **Norata GD**, Buzzi L, Catapano AL, Buccianti G.

Il Bassini 2007; XXVII;12-17.

Triglyceride-rich lipoproteins from normotriglyceridemic subjects and hyperlipidemic patients differently affect endothelial cell activation and gene expression patterns.

Norata GD, Catapano AL.

Circulation Research 2007; 100(7): e81. **IF 9.721**

Triglyceride-rich lipoproteins and endothelial dysfunction: molecular mechanisms and gene expression studies.

Norata GD, Catapano AL.

Future Lipidology 2007;2;119-122.

Molecular mechanisms responsible for the anti-inflammatory and protective effect of HDL on the endothelium.

Norata GD, Catapano AL.

High Blood Pressure & Cardiovascular Prevention, 2007;14:21-31.

Effect of the -420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and renal dysfunction.

Norata GD, Ongari M, Garlaschelli K, Tibolla G, Grigore L, Raselli S, Vettoretti S, Baragetti I, Noto D, Cefalù AB, Buccianti G, Averna M, AL Catapano.

Journal of Internal Medicine, 2007;262:104-112. **IF 4.901**

Plasma resistin levels correlate with determinants metabolic syndrome.

Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL.

European Journal of Endocrinology 2007;156:279-284. **IF 3.239**

Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies.

Norata GD, Grigore L, Raselli S, Redaelli L, Hamsten A, Maggi F, Eriksson P, Catapano AL.

Atherosclerosis 2007;193: 321-327. **IF 4.287**

Anti-inflammatory and anti-atherogenic effects of catechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice.

Norata GD, Passamonti S, Marchesi P, Pirillo A, Violi F, Catapano AL.

Atherosclerosis 2007;191:265-271. **IF 4.287**

Effects of fractalkine receptor variants on common carotid artery intima-media thickness.

Norata GD, Garlaschelli K, Ongari M, Raselli S, Grigore L, Catapano AL.
Stroke 2006;37:1558-61 **IF 5.391**

Oxidized-HDL3 modulates the expression of Cox-2 in human endothelial cells.

Callegari E, **Norata GD**, Inoue H, Catapano AL.
International Journal of Molecular Medicine 2006;18:209-13. **IF 1.867**

HDL and endothelial function: from molecular mechanisms to clinical observations.

Norata GD, Raselli S, Catapano AL.
Future Lipidology 2006;1:343-355.

Triglyceride-rich lipoproteins from hypertriglyceridemic subjects induce a proinflammatory response in the endothelium: molecular mechanisms and gene expression studies.

Norata GD, Grigore L, Raselli S, Seccomandi P, Hamsten A, Maggi FM, Eriksson P, Catapano AL.
Journal of Molecular and Cellular Cardiology 2006;40:484-494. **IF 4.859**

In vitro isolation of circulating endothelial progenitor cells is related to high density lipoprotein plasma levels.

Pellegatta F, Bragheri M, Grigore L, Raselli S, Maggi FM, Brambilla C, Reduzzi A, Pirillo A, **Norata GD**, Catapano AL.
International Journal of Molecular Medicine 2006; 17:203-208. **IF 1.854**

Modified HDL: biological and physiopathological consequences.

Norata GD, Pirillo A, Catapano AL
Nutrition Metabolism and Cardiovascular Disease 2006;16:371-386. **IF 1.867**

Dihydrotestosterone decreases tumor necrosis factor α and lipopolysaccharide induced endothelial inflammatory response.

Norata GD, Tibolla G, Seccomandi PM, Poletti A, Catapano AL.
Journal of Clinical Endocrinology and Metabolism 2006; 91:546-554. **IF 5.799**

Effects of the TLR4 variants on intima media thickness and monocyte-derived macrophage response to LPS.

Norata GD, Garlaschelli K, Raselli S, Grigore L, Benvenuto F, Maggi FM, Catapano AL.
Journal of Internal Medicine 2005; 257:1-7. **IF 4.040**

Liver X receptor and retinoic X receptor agonist modulate the expression of genes involved in lipid metabolism in human endothelial cells.

Norata GD, Ongari M, Uboldi P, Pellegatta F, Catapano AL.
International Journal of Molecular Medicine 2005; 16: 717-723. **IF 2.090**

Molecular mechanisms responsible for the anti-inflammatory and protective effect of HDL on the endothelium.

Norata GD, Catapano AL
Vascular Health and Risk Management 2005; 1:119-129.

High-density lipoproteins induce transforming growth factor beta 2 expression in human endothelial cells.

Norata GD, Callegari E, Marchesi M, Chiesa G, Eriksson P, Catapano AL
Circulation 2005;111:2805-2811. **IF 11.632**

Oxidized-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38 MAPK activation and mRNA stabilization.

Norata GD, Banfi C, Pirillo A, Tremoli E, Hamsten A, Catapano AL, Eriksson P
British Journal of Haematology 2004; 127:97-104. **IF 3.195**

Matrix metalloproteinase-26 (matrylisin-2) expression is high in endometrial hyperplasia and decreases with loss of histologic differentiation in endometrial cancer. Pilka R, **Norata GD**, Domanski H, Hansson S, Eriksson P, Casslen B.

Gynecologic Oncology 2004; 94:661-670. **IF 2.083**

Native LDL and Ox-LDL modulate cyclooxygenase-2 expression in HUVECs through a p38-MAPK NF- κ B, CRE dependent pathways and effects on PGE2 synthesis.

Norata GD, Pirillo A, Pellegatta F, Inoue H, Catapano AL.

International Journal of Molecular Medicine 2004; 14:353-359. **IF 3.190**

Tryglicerides rich lipoproteins and atherosclerosis: in vitro and in vivo studies.

Norata GD, Raselli S, Grigore L, Maggi FM, Catapano AL.

International Congress Series, 2004;1262:507-510.

High Density lipoproteins induce cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE dependent pathway: Effects on COX-2/PGI-S coupling.

Norata GD, Callegari E, Inoue H, Catapano AL.

Arteriosclerosis Thrombosis Vascular Biology 2004;24:871-877. **IF 7.432**

High density lipoprotein subfraction 3 decreases ADAMTs-1 expression induced by LPS and TNF α in human endothelial cells.

Norata GD, Bjork H, Hamsten A, Catapano AL, Eriksson P.

Matrix Biology 2004;22:557-560. **IF 4.104**

Lipid lowering activity of drugs affecting cholesterol absorption

Norata GD, Catapano AL.

Nutrition Metabolism Cardiovascular Disease 2004;14:42-51. **IF 1.253**

Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and Oxidised VLDL.

Norata GD, Pirillo A, Callegari E, Hamsten A, Catapano AL, Eriksson P.

Cardiovascular Research 2003;59:169-180. **IF 5.164**

Effects of high density lipoprotein subfraction 3 on the expression of matrix-degrading proteases in human endothelial cells.

Norata GD, Pellegatta F, Hamsten A, Catapano AL, Eriksson P.

International Journal of Molecular Medicine 2003;12:73-8. **IF 1.940**

Statins and oxidative stress during atherogenesis

Norata GD, Pirillo A, Catapano AL.

European Journal of Preventive Cardiology 2003;10:181-9. **IF 1.990**

PPARs e Patologie Cardiovascolari.

Norata GD, Pellegatta F, Catapano AL

Italian Heart Journal Supplement 2003;4:8-18.

Peroxisome proliferation activated receptors and cardiovascular disease

Norata GD, Pellagatta F, Catapano AL

Italian Heart Journal, Supplement 2003

Peroxisome proliferation activated receptors and cardiovascular disorders

Norata GD, Pellagatta F, Catapano AL

Italian Heart Journal, Supplement 2002

Apoptosis and proliferation of endothelial cells in early atherosclerotic lesions: a possible role for oxidized LDL.

Norata GD, Tonti L, Roma P, Catapano AL.

Nutrition Metabolism Cardiovascular Disease. 2002;12:297-305. **IF 1.679**

Lipoproteine ossidate e endotelio.

Pirillo A, **Norata GD**, Catapano AL.

Giornale dell'aterosclerosi. 2002;27:53-57.

Overexpression of Inducible Heat Shock Protein 70 in COS-1 cells fails to protect from cytotoxicity of oxidized LDLs.

Pirillo A, **Norata GD**, Zanelli T, Catapano AL.

Arteriosclerosis Thrombosis Vascular Biology 2001;21:348-354. **IF 5.816**

Oxidized lipoproteins and endothelium
 Pirillo A, Zhu W, **Norata GD**, Zanelli T, Barberi L, Roma P, Catapano AL.
 Clinical Chemistry and Laboratory Medicine, 2000;38:155-160. **IF 1.744**

**REVISORE PER LE SEGUENTI
 RIVISTE SCIENTIFICHE**

Acta Biochimica et Biophysica Sinica
 Acta Diabetologica
 Aging Health
 American Journal of Pathology
 American Journal of Physiology: Endocrinology and Metabolism
 American Journal of Human Biology
 Annals of Medicine
 Arteriosclerosis Thrombosis Vascular Biology
 Atherosclerosis
 Biochemical Pharmacology
 Biochimica et Biophysica Acta
 Biomarkers
 British Journal of Haematology
 Cell Proliferation
 Clinica Chimica Acta
 Clinical Chemistry and Laboratory Medicine
 Clinical Journal of American Society of Nephrology
 Clinical Endocrinology
 Clinical and Experimental Medicine
 Clinical Nutrition
 Cytokine
 Diabetes Research and Clinical Practice
 Diabetologia
 Expert Review of Cardiovascular Therapy
 European Journal of Endocrinology
 European Journal of Lipid Science and Technology
 European Journal of Pharmacology
 FEBS letter
 Future Cardiology
 Heart and Vessels
 Hypertension
 Human Immunology
 International Journal of Obesity
 Journal of Atherosclerosis and Thrombosis
 Journal of the American College of Nutrition
 Journal of Biological Regulators
 Journal of Diabetes and Its Complications
 Journal of Endocrinology
 Journal of Internal Medicine
 Journal of Leukocyte Biology
 Life Sciences
 Maturitas
 Mediators of Inflammation
 Medical Science Monitoring
 Metabolism
 Nutrition Metabolism and Cardiovascular Disease
 Obesity
 Pharmaceutical Biology
 Pharmacological Research
 Stroke
 Thrombosis and Haemostasis
 The Scandinavian Journal of Clinical & Laboratory Investigation
 The Scandinavian Journal of Rheumatology

Tohoku Journal of Experimental Medicine
Toxicology Letters
Vascular Health and Risk Management

**REVISORE DI RICHIESTE DI
FINANZIAMENTO PER LE
SEGUENTI ISTITUZIONI DI RICERCA**

Ministero Italiano dell'università e della Ricerca (MIUR), Italy.
Agence Nationale de la Recherche, France.
Dutch Diabetes Research Foundation, The Netherlands.
South African Medical Research Council, South Africa.
Conacuoere Onlus, PRICARD grants, Italy.
Research Foundation Flanders, Belgium.
European project RBUCE-UP, France.
Diabetes UK, United Kingdom.

**MEMBRO DEL COMITATO
ORGANIZZARE DEI SEGUENTI
CONGRESSI**

First International Meeting on PPARs: from basic science to clinical applications.
Florence 2001
6th International Meeting on global risk assessment in cardiovascular disease and stroke.
Florence 2002
Second International Meeting on PPARs: from basic science to clinical applications.
Florence 2003
XV International Symposium on Drugs Affecting Lipid Metabolism. Venice 2004
80th European Atherosclerosis Society meeting, Milan 2012.
35th European Lipoprotein Club Meeting, Tutzing, Germany 2012.
81st European Atherosclerosis Society meeting, Lyon 2013. Poster Award Committee.
36th European Lipoprotein Club Meeting, Tutzing, Germany 2013.
82nd European Atherosclerosis Society meeting, Madrid 2014. Poster Coordinator.
37th European Lipoprotein Club Meeting, Tutzing, Germany 2014.
83rd European Atherosclerosis Society meeting, Glasgow 2015. Poster Coordinator and Young Investigators chairs.
38th European Lipoprotein Club Meeting, Tutzing, Germany 2015.
84th European Atherosclerosis Society meeting, Innsbruck 2016. Congress Committee
85th European Atherosclerosis Society meeting, Prague 2017. Scientific Committee

**PREMI, RICONOSCIMENTI E
FINANZIAMENTI PER LA RICERCA**

1997: Premio SISA (Società Italiana Studio Aterosclerosi)
1997: Finalista per il Young Award Investigator all'XI International Symposium on Atherosclerosis, Paris
1999: Premio giovani ricervatori SISA.
2000: Premio SISA
2000: Finalista per il Young Award Investigator all'XII International Symposium on Atherosclerosis, Stockholm
2001: Grant del MIUR (Ministero Istruzione Università e Ricerca) per il progetto: "In vitro studies on the inflammatory response induced by post-prandial lipoproteins in endothelial cells"
2002: Premio giovani ricercatori SISA
2003: Premio giovani ricercatori SISA
2004: Premio giovani ricercatori SISA e SISA Lombardia
2005: Premio giovani ricercatori consegnato da European Lipoprotein Club
2006: Premio giovani ricercatori SISA
2009: Premio SISA per giovani ricercatori
2010: Premio giovani ricercatori European Atherosclerosis Society
2010: Premio giovani ricercatori MAJORS: the Metabolic Atherosclerotic Joint Regional Symposium, Dublin.
2011: Grant della Fondazione Cariplo per il progetto: "Role of Micro RNA's 143 and 145 in cardiovascular physiology and disease: from bench to bedside"
2011-2013: Grant from Fondazione Cariplo (2010-0768) for the project: "Role of Micro RNA's 143 and 145 in cardiovascular physiology and disease: from bench to bedside".
2012-2014: COST action (BM0904_HDLnet). "HDL: From Biological Understanding to Clinical Exploitation".
2013-2016: Grant from Telethon Foundation (GGP13002) for the project: "Engineered T regulatory cells to control the immune-inflammatory response and the accelerated onset of

atherosclerosis in familial hypercholesterolemia".

2014: Grant from UNIMI: Piano Sviluppo B.

2014-2017: Grant from Ministry of Health (GR-2011-02346974) for the project: "Targeting inflammation in atherosclerosis: role and therapeutic potential of sphingosine 1-phosphate (S1P) and its receptors".

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 196/03.

A handwritten signature in blue ink, appearing to read 'G. Norata', with a long horizontal stroke extending to the right.

Prof. Giuseppe Danilo Norata